Lorlatinib, an orally administered inhibitor of anaplastic lymphoma kinase (ALK) and ROS1, was administered in patients with ALK rearrangement pursuant to the findings observed in lung cancer (Shaw et al. 2020). This evidence concerns the gene ALK and lung cancer.